Medtronic ordered to pay out $15.4M; Eurofins buys U.S. Dx outfit for $255M;

@FierceMedDev: Report: Cinven shopping French Dx company Sebia. More | Follow @FierceMedDev

@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Double-locked virus needs two enzyme 'keys' to release drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Doctors weigh in on Wikipedia as an evolving--yet flawed--medical text: More from The Atlantic | Follow @EmilyWFierce

> A federal jury has ordered Medtronic ($MDT) to pay $15.4 million to Pabban Development, a company it agreed to acquire in 2008, ruling that the med tech giant didn't follow through on its promises. Article

> Paris' Eurofins has signed up to acquire diagnostics outfit ViraCor-IBT Laboratories from majority owner Ampersand Capital for $255 million. More

Biotech News

@FierceBiotech: Show me the money: Which drugs made the top 10 list on upfront deals? Special Report | Follow @FierceBiotech

@JohnCFierce: Lilly draws flak after touting PhIII diabetes success for Lantus rival. More | Follow @JohnCFierce

@DamianFierce: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. Story | Follow @DamianFierce

@EmilyMFierce: Potential measles exposure in Fairfax, Loudoun counties investigated. More from The Washington Post | Follow @EmilyMFierce

> Pfizer makes a case for R&D in AstraZeneca megamerger, but does anyone believe it? More

> Chase banks $21M round for Alzheimer's drug research. Item

> Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant. Story

Pharma News

@FiercePharma: Allergan board dismisses Valeant bid, but is it running out of options? Report | Follow @FiercePharma

@TracyStaton: Tops online this weekend: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @TracyStaton

@EricPFierce: Problems just keep mounting up for Novartis in Japan, this time over events reporting. News | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Pfizer prepares to file for approval with positive PhII MenB data. FierceVaccines story | Follow @CarlyHFierce

> Parsing Pfizer's deal talk isn't an exercise. It's the tell on AstraZeneca's future. Story

> Desperate to ward off Copaxone copies, Teva sues FDA. More

> On a quest to double sales, Akorn snags specialized rival VersaPharm in $440M deal. Article

CRO News

> Icon wraps up its $143.5M deal for Aptiv. Item

> China's Tigermed buys a $50M stake in a U.S. CRO. Article

> AMRI posts flat revenue as transitional year marches on. More

> Royalty Pharma backs risk-friendly researcher Avillion. Story

> Huntingdon buys Harlan Labs in a bet on CRO growth. Report

Biotech IT News

> Faced with FDA barriers, 23andMe mulls overseas expansion. Item

> U.K. tries to revive 'dead duck' patient data sharing plan. Report

> Debiopharm inks deal with Yale to access computer-aided drug discoveries. Story

> Flatiron raises $130M in Google-led round, buys EMR business. More

> DrugDev buys TrialNetworks to 'glue' its clinical trial apps together. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.